$14.36
0.95% day before yesterday
NYSE, Dec 27, 09:47 pm CET
ISIN
CA98985W1023
Symbol
ZYME
Sector
Industry

Zymeworks Inc. Stock price

$14.50
+0.08 0.55% 1M
+6.09 72.41% 6M
+4.11 39.56% YTD
+3.75 34.88% 1Y
-1.32 8.34% 3Y
-30.15 67.53% 5Y
+1.50 11.54% 10Y
NYSE, Closing price Fri, Dec 27 2024
+0.00 0.00%
ISIN
CA98985W1023
Symbol
ZYME
Sector
Industry

Key metrics

Market capitalization $1.01b
Enterprise Value $730.05m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 11.74
P/S ratio (TTM) P/S ratio 16.19
P/B ratio (TTM) P/B ratio 2.77
Revenue growth (TTM) Revenue growth -86.52%
Revenue (TTM) Revenue $62.20m
EBIT (operating result TTM) EBIT $-121.03m
Free Cash Flow (TTM) Free Cash Flow $-54.68m
Cash position $297.20m
EPS (TTM) EPS $-1.51
P/E forward negative
P/S forward 11.25
EV/Sales forward 8.16
Short interest 8.29%
Show more

Is Zymeworks Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Zymeworks Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Zymeworks Inc. forecast:

6x Buy
75%
2x Hold
25%

Analyst Opinions

8 Analysts have issued a Zymeworks Inc. forecast:

Buy
75%
Hold
25%

Financial data from Zymeworks Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
62 62
87% 87%
100%
- Direct Costs 11 11
33% 33%
17%
51 51
88% 88%
83%
- Selling and Administrative Expenses 38 38
28% 28%
62%
- Research and Development Expense 123 123
28% 28%
198%
-110 -110
150% 150%
-177%
- Depreciation and Amortization 11 11
33% 33%
17%
EBIT (Operating Income) EBIT -121 -121
159% 159%
-195%
Net Profit -114 -114
155% 155%
-183%

In millions USD.

Don't miss a Thing! We will send you all news about Zymeworks Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Zymeworks Inc. Stock News

Positive
Seeking Alpha
10 days ago
The Zymeworks story over the last two years was one of transformation and execution. Ziihera (zanidatamab) was approved in November for the treatment of second line biliary tract cancer and Zymeworks should start generating royalties on net sales this quarter. The phase 3 results for Ziihera in first-line GEA patients are now expected in Q2 2025, and represent the next critical step for Zymewor...
Neutral
GlobeNewsWire
about one month ago
VANCOUVER, British Columbia, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that management will participate in the following upcoming investor conferences:
Neutral
GlobeNewsWire
about one month ago
VANCOUVER, British Columbia, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced, with Jazz Pharmaceuticals, that the U.S. Food and Drug Administration (FDA) has granted accelerated approval o...
More Zymeworks Inc. News

Company Profile

Zymeworks, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development and commercialization of biotherapeutics. Its product, ZW25 and ZW49 are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada.

Head office Canada
CEO Ken Galbraith
Employees 277
Founded 2003
Website www.zymeworks.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today